Technavio has announced their latest pipeline analysis report on
market. The report includes a detailed analysis of the pipeline
molecules under investigation within the defined data collection period
to treat tuberculosis.
This press release features multimedia. View the full release here:
Technavio has published a new report on the drug development pipeline for tuberculosis, including a detailed study of the pipeline molecules. (Graphic: Business Wire)
This report presents a detailed analysis of the market, including
regulatory framework, drug development strategies, recruitment
strategies, and key companies that are expected to play an essential
role in the growth of the market in the future.
THIS REPORT IS AVAILABLE AT A USD 1,000 DISCOUNT FOR A LIMITED TIME
MARKET SNAPSHOT BEFORE PURCHASING
Tuberculosis: Market overview
Tuberculosis is a disease caused by a bacterium called Mycobacterium
tuberculosis. This bacterium is present in the air and spreads from one
person to another. It usually affects the lungs and can also target
other body parts, including the spine, brain, and kidney.
According to a senior market research analyst at Technavio for research
on infectious and rare diseases, “Research study shows that 10.4
million people worldwide became sick with tuberculosis in 2016.
Furthermore, 1.7 million TB-related deaths were reported worldwide. In
2012, there were 122 cases per 100,000 population, in which most of the
cases were from Africa, Western Pacific, Eastern Mediterranean region,
Europe, and the Americas.”
Tuberculosis: Segmentation analysis
This pipeline analysis report segments the tuberculosis market based on
therapies employed (monotherapy and combination therapy), RoA (oral,
intradermal, intramuscular, and subcutaneous), therapeutic modality
(small molecule, vaccine, and biological), targets (cell wall, DprE1
protein, adenosine triphosphatase, fatty acid synthetase complex,
leucyl-tRNA synthetase, mycobacterial DNA, phosphotransferase, protein
30S ribosomal subunit, protein kinase, and protein synthesis), MoA
(immune stimulator, cell wall inhibitor, DprE1 protein inhibitor,
adenosine triphosphatase inhibitor, fatty acid synthetase complex
inhibitor, leucyl-tRNA synthetase inhibitor, mycobacterial DNA
inhibitor, phosphotransferase inhibitor, protein 30S ribosomal subunit
inhibitor, protein kinase inhibitor, and protein synthesis inhibitor),
geographical segmentation (the US, the Philippines, South Africa,
Russia, Kenya, and India), and recruitment status (completed,
recruiting, not yet recruiting, active,not recruiting, and terminated).
It provides an in-depth analysis of the prominent factors influencing
the market, including drivers, opportunities, trends, and
LOOKING FOR MORE INFORMATION ON THIS MARKET? REQUEST
A FREE SAMPLE REPORT
Technavio’s sample reports are free of charge and contain multiple
sections of the report such as the market size and forecast, drivers,
challenges, trends, and more.
Some of the key topics covered in the report include:
Scope of the Report
Drug Development Landscape
Drug Development Strategies
Discontinued or Dormant Molecules
is a leading global technology research and advisory company. Their
research and analysis focuses on emerging market trends and provides
actionable insights to help businesses identify market opportunities and
develop effective strategies to optimize their market positions.
With over 500 specialized analysts, Technavio’s report library consists
of more than 10,000 reports and counting, covering 800 technologies,
spanning across 50 countries. Their client base consists of enterprises
of all sizes, including more than 100 Fortune 500 companies. This
growing client base relies on Technavio’s comprehensive coverage,
extensive research, and actionable market insights to identify
opportunities in existing and potential markets and assess their
competitive positions within changing market scenarios.
If you are interested in more information, please contact our media team
View source version on businesswire.com: https://www.businesswire.com/news/home/20180710005823/en/